tbuckley/cabot-search huggingface dataset:
Taking Systems Medicine to Heart
Authors: Kalliopi Trachana, Rhishikesh Bargaje, Gustavo Glusman, Nathan D. Price, Sui Huang, Leroy E. Hood
Journal: Circulation Research (2018)

Systems medicine is a holistic approach to deciphering the complexity of human physiology in health and disease. In essence, a living body is constituted of networks of dynamically interacting units (molecules, cells, organs, etc) that underlie its collective functions. Declining resilience because of aging and other chronic environmental exposures drives the system to transition from a health state to a disease state; these transitions, triggered by acute perturbations or chronic disturbance, manifest as qualitative shifts in the interactions and dynamics of the disease-perturbed networks. Understanding health-to-disease transitions poses a high-dimensional nonlinear reconstruction problem that requires deep understanding of biology and innovation in study design, technology, and data analysis. With a focus on the principles of systems medicine, this Review discusses approaches for deciphering this biological complexity from a novel perspective, namely, understanding how disease-perturbed networks function; their study provides insights into fundamental disease mechanisms. The immediate goals for systems medicine are to identify early transitions to cardiovascular (and other chronic) diseases and to accelerate the translation of new preventive, diagnostic, or therapeutic targets into clinical practice, a critical step in the development of personalized, predictive, preventive, and participatory (P4) medicine.
Prostate-Specific Antigen (PSA) Screening for Prostate Cancer
Authors: H. Ballentine Carter
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Engineering Pro‐Regenerative Hydrogels for Scarless Wound Healing
Authors: Guoming Sun, Yu‐I Shen, John W. Harmon
Journal: Advanced Healthcare Materials (2018)

Abstract Skin and skin appendages protect the body from harmful environment and prevent internal organs from dehydration. Superficial epidermal wounds usually heal without scarring, however, deep dermal wound healing commonly ends up with nonfunctioning scar formation with substantial loss of skin appendage. Wound healing is one of the most complex dynamic biological processes, during which a cascade of biomolecules combine with stem cell influx and matrix synthesis and synergistically contribute to wound healing at all levels. Although many approaches have been investigated to restore complete skin, the clinically effective therapy is still unavailable and the regeneration of perfect skin still remains a significant challenge. The complete mechanism behind scarless skin regeneration still requires further investigation. Fortunately, recent advancement in regenerative medicine empowers us more than ever to restore tissue in a regenerative manner. Many studies have elucidated and reviewed the contribution of stem cells and growth factors to scarless wound healing. This article focuses on recent advances in scarless wound healing, especially strategies to engineer pro‐regenerative scaffolds to restore damaged skin in a regenerative manner.
Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study
Authors: B. Hajarizadeh, J. Grebely, M. Byrne, P. Marks, J. Amin, T. Butler, P. Vickerman, N. Martin, J.G. Mchutchison, D. Brainard, C. Treloar, A. Lloyd, G. Dore
Journal: Journal of Hepatology (2018)
Analyses of intermediate stage hepatocellular carcinoma patients from the point of view of designing clinical trials comparing transarterial chemoembolization and systemic therapies
Authors: K. Koroki, S. Ogasawara, Y. Ooka, M. Inoue, T. Chiba, E. Suzuki, M. Yokoyama, T. Maeda, T. Wakamatsu, K. Kobayashi, S. Kiyono, M. Nakamura, T. Saito, S. Nakamoto, S. Yasui, A. Tawada, M. Arai, T. Kanda, H. Maruyama, S. Kuboki, M. Miyazaki, O. Yokosuka, M. Ohtsuka, N. Kato
Journal: Journal of Hepatology (2018)
Brief Report: Leg Length Inequality and Hip Osteoarthritis in the Multicenter Osteoarthritis Study and the Osteoarthritis Initiative
Authors: Chan Kim, Michael Nevitt, Ali Guermazi, Jingbo Niu, Margaret Clancy, Irina Tolstykh, Pia M. Jungmann, Nancy E. Lane, Neil A. Segal, William F. Harvey, Cora E. Lewis, David T. Felson
Journal: Arthritis & Rheumatology (2018)

Objective Studies suggest that persons with a leg length inequality ( LLI ) of ≥2 cm have an increased risk of developing knee osteoarthritis ( OA ) in that limb. The present study was undertaken to examine whether LLI also confers an increased risk of hip OA . Methods Using long limb radiographs from subjects in the Multicenter Arthritis Study ( MOST ) and the Osteoarthritis Initiative ( OAI ), we measured LLI and scored hip radiographs that were obtained at baseline and 3–5‐year follow‐up. The associations of LLI of ≥1 cm and LLI of ≥2 cm with radiographic hip OA were examined cross‐sectionally and longitudinally, assessing risk in shorter limbs and longer limbs compared to limbs from subjects with no LLI . We carried out logistic regression analyses with generalized estimating equations and adjusted for age, sex, body mass index, height, and cohort of origin. Results There were 1,966 subjects from the MOST and 2,627 subjects from the OAI . Twelve percent had LLI of ≥1 cm and 1% had LLI of ≥2 cm. For LLI ≥1 cm, the adjusted odds ratio for prevalent hip OA in the shorter leg was 1.47 (95% confidence interval [95% CI ] 1.07–2.02) and for LLI ≥2 cm, it was 2.15 (95% CI 0.87–5.34). For LLI ≥1 cm, the odds of incident hip OA in the shorter leg were 1.39 (95% CI 0.81–2.39) while for LLI ≥2 cm, they were 4.20 (95% CI 1.26–14.03). We found no increased risk of hip OA in longer limbs. Conclusion Our findings suggest that, as with knee OA , legs that are at least 2 cm shorter than the contralateral leg are at increased risk of hip OA .
P487Analysis of cardioprotection efficiency in case of acute myocardial infarction
Authors: V K Tashchuk, M V Tashchuk, P R Ivanchuk
Journal: Cardiovascular Research (2018)

divided into at least three cell populations: Classical monocytes (CM; CD14þþCD16-), intermediate monocytes (IM; CD14þþCD16þCCR2þ) and non-classical monocytes (NCM; CD14þCD16þþCCR2-).Purpose: The aim of this study was to analyze whether monocyte subset distribution is associated with 30-day survival in patients with AHF.Methods: We included 90 consecutive patients with AHF (33% with cardiogenic shock, 21% with acutely decompensated HF and 46% of patients suffered from AHF after cardiac arrest).Blood was taken at admission and after 72 hours and monocyte subset distribution was analyzed.Results: Mean age was 62.1 6 16.0, 76.7% of patients were male and median NT-proBNP levels were 4986 (1525 -23842) pg/mL.30-day survival was 64.4%.At admission, no association between monocyte subsets and outcome was seen.However on day 4, increased levels of IM (9.4 (4.0-13.8)% vs. 4.3 (2.1-7.9)%; p¼0.02, respectively).and lower levels of CM were predictive of 30-day mortality (86.8 (77.5 -88.9) % vs. 90.5 (84.3 -92.9), p¼ 0.02, respectively), while the NCM proportion was not associated with mortality.Risk of dying was increased 10.6-fold in the lowest tertile of CM and 9.5-fold in patients in the lowest IM tertile (p<0.05 for both).Conclusion: Circulating monocyte subsets are associated with 30-day mortality in patients with AHF requiring ICU admission.Activation status of the innate immune system as reflected by monocyte subset distribution may play a major role in pathophysiology and outcome in this patient cohort.
FDG-PET/CT Focal Uptake on an Ocular Prosthesis
Authors: Alessandra Repetto, Carolina Igua, Pablo Sopena, Pilar Bello
Journal: Clinical Nuclear Medicine (2018)

Abstract We present a case of an unexpected focally increased radiotracer uptake in an artificial eye in an FDG-PET/CT scan that was performed on a woman with a history of choroidal melanoma. It is crucial to know the type of prosthesis used and the timing of replacement for a correct interpretation of the findings. Recently, an FDG PET/CT was proposed to monitor the vascularity of the prosthesis instead of gadolinium MRI or of 99m Tc bone scintigraphy.
Computational modeling guides tissue-engineered heart valve design for long-term in vivo performance in a translational sheep model
Authors: Maximilian Y. Emmert, Boris A. Schmitt, Sandra Loerakker, Bart Sanders, Hendrik Spriestersbach, Emanuela S. Fioretta, Leon Bruder, Kerstin Brakmann, Sarah E. Motta, Valentina Lintas, Petra E. Dijkman, Laura Frese, Felix Berger, Frank P. T. Baaijens, Simon P. Hoerstrup
Journal: Science Translational Medicine (2018)

Computational modeling–inspired heart valve designs guide tissue remodeling and ensure long-term functionality in tissue-engineered heart valves in sheep.
Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma
Authors: Alice Lorenzoni, Antonella Capozza, Salvatore Artale, Marco Maccauro, Ettore Cesare Seregni
Journal: Clinical Nuclear Medicine (2018)

Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.
Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
Authors: Brent R. Weil, Arin L. Madenci, Qi Liu, Rebecca M. Howell, Todd M. Gibson, Yutaka Yasui, Joseph P. Neglia, Wendy M. Leisenring, Susan A. Smith, Emily S. Tonorezos, Danielle N. Friedman, Louis S. Constine, Christopher L. Tinkle, Lisa R. Diller, Gregory T. Armstrong, Kevin C. Oeffinger, Christopher B. Weldon
Journal: Journal of Clinical Oncology (2018)

Purpose Infection-related outcomes associated with asplenia or impaired splenic function in survivors of childhood cancer remains understudied. Methods Late infection-related mortality was evaluated in 20,026 5-year survivors of childhood cancer (diagnosed &lt; 21 years of age from 1970 to 1999; median age at diagnosis, 7.0 years [range, 0 to 20 years]; median follow-up, 26 years [range, 5 to 44 years]) using cumulative incidence and piecewise-exponential regression models to estimate adjusted relative rates (RRs). Splenic radiation was approximated using average dose (direct and/or indirect) to the left upper quadrant of the abdomen (hereafter, referred to as splenic radiation). Results Within 5 years of diagnosis, 1,354 survivors (6.8%) had a splenectomy and 9,442 (46%) had splenic radiation without splenectomy. With 62 deaths, the cumulative incidence of infection-related late mortality was 1.5% (95% CI, 0.7% to 2.2%) at 35 years after splenectomy and 0.6% (95% CI, 0.4% to 0.8%) after splenic radiation. Splenectomy (RR, 7.7; 95% CI, 3.1 to 19.1) was independently associated with late infection-related mortality. Splenic radiation was associated with increasing risk for late infection-related mortality in a dose-response relationship (0.1 to 9.9 Gy: RR, 2.0; 95% CI, 0.9 to 4.5; 10 to 19.9 Gy: RR, 5.5; 95% CI, 1.9 to 15.4; ≥ 20 Gy: RR, 6.0; 95% CI, 1.8 to 20.2). High-dose alkylator chemotherapy exposure was also independently associated with an increased risk of infection-related mortality (RR, 1.9; 95% CI, 1.1 to 3.4). Conclusion Splenectomy and splenic radiation significantly increase risk for late infection-related mortality. Even low- to intermediate-dose radiation exposure confers increased risk, suggesting that the spleen is highly radiosensitive. These findings should inform long-term follow-up guidelines for survivors of childhood cancer and should lead clinicians to avoid or reduce radiation exposure involving the spleen whenever possible.
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Authors: M.-F. Yuen, K. Agarwal, E. Gane, C. Schwabe, W. Cheng, W. Sievert, D.J. Kim, S.H. Ahn, Y.-S. Lim, K. Visvanathan, E. Ruby, S. Liaw, R. Colonno, U. Lopatin
Journal: Journal of Hepatology (2018)
Etiology of splanchnic vein thrombosis in 812 chinese patients from a single center
Authors: J. Fan, Q. Wang, H. Chen, J. Niu, B. Luo, J. Yuan, C. He, W. Bai, W. Guo, J. Tie, K. Li, X. Yuan, T. Yu, Z. Wang, Y. Zhu, N. Han, X. Li, Y. Lv, H. Liu, E. Wang, D. Xia, L. Liu, L. Zuo, Z. Yin, D. Fan, G. Han
Journal: Journal of Hepatology (2018)
Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment
Authors: Adrián H. Teruel, Édgar Pérez-Esteve, Isabel González-Álvarez, Marta González-Álvarez, Ana M. Costero, Daniel Ferri, Margarita Parra, Pablo Gaviña, Virginia Merino, Ramón Martínez-Mañez, Félix Sancenón
Journal: Journal of Controlled Release (2018)
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer
Authors: Jinani Jayasekera, Yisheng Li, Clyde B Schechter, Reshma Jagsi, Juhee Song, Julia White, George Luta, Judith-Anne W Chapman, Eric J Feuer, Richard C Zellars, Natasha Stout, Thomas B Julian, Timothy Whelan, Xuelin Huang, E Shelley Hwang, Judith O Hopkins, Joseph A Sparano, Stewart J Anderson, Anthony W Fyles, Robert Gray, Willi Sauerbrei, Jeanne Mandelblatt, Donald A Berry, Donald A Berry, Judith-Anne W Chapman, Joseph P Costantino, Anthony Fyles, Robert Gray, Judith O Hopkins, Xuelin Huang, E Shelley Hwang, Reshma Jagsi, Jinani Jayasekera, Thomas B Julian, Yisheng Li, George Luta, Jeanne Mandelblatt, Willi Sauerbrei, Clyde B Schechter, Joseph A Sparano, Juhee Song, Stewart J Anderson, Natasha Stout, Timothy Whelan, Julia White, Richard C Zellars, Eric J Feuer
Journal: JNCI Journal of the National Cancer Institute (2018)

We used two models to simulate a proposed noninferiority trial of radiotherapy (RT) omission in low-risk invasive breast cancer to illustrate how modeling could be used to predict the trial's outcomes, inform trial design, and contribute to practice debates.The proposed trial was a prospective randomized trial of no-RT vs RT in women age 40 to 74 years undergoing lumpectomy and endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, stage I breast cancer with an Oncotype DX score of 18 or lower. The primary endpoint was recurrence-free interval (RFI), including locoregional recurrence, distant recurrence, and breast cancer death. Noninferiority required the two-sided 90% confidence interval of the RFI hazard ratio (HR) for no-RT vs RT to be entirely below 1.7. Model inputs included published data. The trial was simulated 1000 times, and results were summarized as percent concluding noninferiority and mean (standard deviation) of hazard ratios for Model GE and Model M, respectively.Noninferiority was demonstrated in 18.0% and 3.7% for the two models. The respective means (SD) of the RFI hazard ratios were 1.8 (0.7) and 2.4 (0.9); most were locoregional recurrences. The mean five-year RFI rates for no-RT vs RT (SD) were 92.7% (2.9%) vs 95.5% (2.2%) and 88.4% (2.0%) vs 94.5% (1.6%). Both models showed little or no difference in breast cancer-specific or overall survival. Alternative definitions of low risk based on combinations of age and grade produced similar results.The proposed trial was unlikely to show noninferiority of omitting radiotherapy even using alternative definitions of low-risk, as the endpoint included local recurrence. Future trials regarding radiotherapy should address absolute reduction in recurrence and impact of type of recurrence on the patient.
P107Cardioprotective cytokine interleukin-33 is upregulated by statins and bisphosphonates in human cardiac cells
Authors: R Pentz, C Kaun, S Stojkovic, K A Krychtiuk, A Zuckermann, K Huber, P Hohensinner, J Wojta, S Demyanets
Journal: Cardiovascular Research (2018)

Methods: Twenty-eight healthy male Wistar rats were divided into two groups, receiving vehicle (Control; n¼13) or ivabradine (IVA; 10 mg/kg/day; n¼15) in the drinking water for three consecutive weeks.All rats were implanted with radiotelemetry ECG devices and 72-h continuous ECG monitoring was performed in freely moving rats.Heart rate variability indexes in the time and frequency domains were evaluated.Results: As expected, ivabradine significantly decreased resting heart rate (351629 bpm in Control vs. 294631 bpm in IVA; p<0.0001).Chronic ivabradine treatment was associated with increased standard deviation of normal-to-normal intervals (SDNN; 27.366.4ms vs. 17.963.8ms; p<0.0001), root mean square differences of successive R-R intervals (RMSSD; 5.761.4ms vs. 2.760.6 ms; p<0.0001), proportion of successive R-R intervals difference >50 ms (pNN50; 0.2960.09% vs. 0.0760.04%;p<0.0001), as well as with increased total power (44.2617.3ms2 vs. 16.967.1 ms2; p<0.0001), normalized high (HF)-(28.6612.5% vs. 16.365.3%;p<0.01) and low (LF)-frequency (6.161.5% vs. 4.361.9%;p¼0.01) power.LF/HF ratios were not affected by ivabradine (0.260.1 vs. 0.360.1;p¼0.43).Conclusions: In healthy rats, ivabradine administration significantly increased parasympathetic activity, as reflected by the higher RMSSD, pNN50, and HF values in this group.However, the lack of change in the LF/HF ratios points towards simultaneous sympathetic activation.This ivabradineinduced sympatho-vagal coactivation could contribute to the increased propensity to atrial fibrillation reported in ivabradine-treated patients.
Testing and linkage to care outcomes in baby boomers versus young adults tested in the community and linked to care at a Federally Qualified Health Center in the US
Authors: L. Magaldi, N. Brown, C. Coleman, M. Dorshimer, J. Kostman, D. Zaret, T-W. Preston, M. Reddy, R. Rivera, S. Trooskin
Journal: Journal of Hepatology (2018)
No Evident Disease Activity—More Than a Risky Ambition?
Authors: Benjamin Meir Jacobs, Gavin Giovannoni, Klaus Schmierer
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Therapy with DAAs in patients with chronic hepatitis C and advanced chronic kidney disease: Real-world experience from the German Hepatitis C-Registry (DHC-R)
Authors: J. Wiegand, P. Buggisch, S. Mauss, K. Boeker, H. Klinker, T. Müller, R. Guenther, Y. Serfert, M.P. Manns, S. Zeuzem, T. Berg, H. Hinrichsen, D.H. C-Register
Journal: Journal of Hepatology (2018)
Management appropriateness and outcomes of patients with acute pulmonary embolism
Authors: David Jiménez, Behnood Bikdeli, Deisy Barrios, Raquel Morillo, Rosa Nieto, Ina Guerassimova, Alfonso Muriel, Luis Jara-Palomares, Lisa Moores, Victor Tapson, Roger D. Yusen, Manuel Monreal
Journal: European Respiratory Journal (2018)

The impact of adherence to published guidelines on the outcomes of patients with acute pulmonary embolism (PE) has not been well defined by previous studies. In this prospective cohort study of patients admitted to a respiratory department (n=2096), we evaluated whether patients with PE had better outcomes if they were acutely managed according to international guidelines. Outcomes consisted of all-cause mortality, PE-related mortality, recurrent venous thromboembolism (VTE) and major bleeding events during the first month of follow-up after diagnosis. Overall, 408 patients (19% (95% CI 18–21%)) did not receive guideline-adherent PE management. Patients receiving non-adherent management were significantly more likely to experience all-cause mortality (adjusted odds ratio (OR) 2.39 (95% CI 1.57–3.61) or PE-related mortality (adjusted OR 5.02 (95% CI 2.42–10.42); p&lt;0.001) during follow-up. Non-adherent management was also a significant independent predictor of recurrent VTE (OR 2.19 (95% CI 1.11–4.32); p=0.03) and major bleeding (OR 2.65 (95% CI 1.66–4.24); p&lt;0.001). An external validation cohort of 34 380 patients with PE from the RIETE registry confirmed these findings. PE management that does not adhere to guidelines for indications related to anticoagulation, thrombolytics and inferior vena cava filters is associated with worse patient outcomes.
Lack of Information on Surgical Care for Incarcerated Persons
Authors: Sara Scarlet, Anthony A. Meyer, Elizabeth B. Dreesen
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal